Search Resources (English): Women and Health Protection (WHP)

Results 21 - 30 of 63

Results

Women and adverse drug reactions: reporting in the Canadian context  
http://www.whp-apsf.ca/pdf/fullerReport.pdf
Provides an overview of how Canada's program for reporting Adverse Drug Reactions (ADRs) supports-or doesn't support-an effective women's health strategy related to prescription drug use. (See Details)
Published: 2002, 2003
Reporting harm caused by medicines  
http://www.whp-apsf.ca/en/documents/adrReport.html
Discusses why women should report all cases of known or suspected harm from prescription drugs and medicines. Provides contact information for consumers who wish to file a report. (See Details)
Published: 2005
Who benefits: international harmonisation of the regulation of new pharmaceutical drugs  
http://www.whp-apsf.ca/en/documents/who_benefits.html
Explains how the push to streamline the drug approval process in the world's three largest pharmaceutical markets is neglecting the special needs of women. (See Details)
Published: 2002
Widespread use of SSRI antidepressants drives soaring health care costs in Canada/What are SSRI antidepressants?  
http://www.cwhn.ca/node/39462
Questions the science behind SSRI antidepressants and their real-world effectiveness. Examines why so many SSRIs are prescribed to women, as well as safety concerns and alternative treatment options. (See Details)
Published: 2006
Post-market surveillance of therapeutic drugs in Canada  
http://www.whp-apsf.ca/en/documents/adrBackground.html
Discusses the importance of an effective post-market surveillance system of therapeutic drugs. Lists problems with the current system, and argues that improvements will only occur when there is greater consumer involvement. (See Details)
Published: 2005
Preventing disease: are pills the answer?  
http://www.whp-apsf.ca/en/documents/pills_prevent.html
Discusses the different roles of public health and medicine. Argues that the boundaries between the two are blurring with the popularity of chemoprevention. (See Details)
Published: 2002
Drug company funding dominates non-profit organizations, report finds  
http://www.cwhn.ca/node/39464
Provides highlights of a Women and Health Protection report that describes the ways in which drug companies provide funding for health advocacy groups. (See Details)
Published: 2006
Same tune, different lyrics: the Vioxx story  
http://www.cwhn.ca/node/39500
Illustrates the flaws in the Canadian drug approval and drug regulatory processes, using the current Vioxx scandal as example. (See Details)
Published: 2005
Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross secti  
http://bmj.bmjjournals.com/cgi/content/full/324/7332/278
Examines the relation between direct to consumer advertising and patients' requests for prescriptions and the relation between patients' requests and prescribing decisions. (See Details)
Published: 2002
Remembering Ruth Cooperstock: women and pharmaceuticals 20 years later  
http://www.whp-apsf.ca/pdf/coopProceedingsEN.pdf
Presents the proceedings of a symposium that examined women and the pharmaceuticals industry. Includes presentations of the three panellists and a brief summary of each of the workshops. (See Details)
Published: 2006